Bivalirudin: Uses, Mechanism, and Side Effects

Patients scheduled for a coronary procedure are often asked about blood thinners, and bivalirudin is one option doctors may use during the intervention. Understanding how it works and what it is approved for can help make sense of its role in the procedure room.

Key takeaways

• Bivalirudin is a direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention (PCI).
• It is approved for use in PCI patients, including those with heparin-induced thrombocytopenia (HIT) or HIT with thrombosis syndrome.
• More than 100 trials have studied bivalirudin, including comparisons to heparin-based regimens.
• The most frequently reported adverse events in safety databases relate to bleeding and reduced effectiveness, not a single dominant reaction.
• Bivalirudin carries no boxed warning on its current label.

What Bivalirudin Is

Bivalirudin belongs to the anticoagulant class and is specifically classified as a direct thrombin inhibitor. It works by binding directly to thrombin, a protein central to blood clot formation, blocking both its active site and a secondary binding region. By inhibiting thrombin, bivalirudin prevents it from converting fibrinogen into fibrin, the mesh-like protein that stabilizes clots, and also blocks thrombin's activation of other clotting factors.

What Bivalirudin Is Approved For

Bivalirudin is approved as an anticoagulant for patients undergoing percutaneous coronary intervention, a procedure used to open narrowed or blocked coronary arteries. Its approved use specifically includes patients who have heparin-induced thrombocytopenia or heparin-induced thrombocytopenia with thrombosis syndrome, conditions that make standard heparin therapy unsuitable. The label does not carry a boxed warning.

What the Evidence Shows

Bivalirudin has been studied in 105 registered clinical trials. One completed Phase 3 trial compared bivalirudin to a heparin and protamine regimen in patients undergoing cardiopulmonary bypass surgery. Another trial examined bivalirudin given before hospital arrival to patients experiencing a specific type of heart attack (STEMI), and this trial was also completed.

Reported Side Effects

Reports submitted to adverse event databases most commonly describe the drug being ineffective or used off label, together accounting for the largest share of entries. Bleeding-related terms form the next major pattern, including general haemorrhage (87 reports) and gastrointestinal haemorrhage (43 reports). Clotting-related events also appear, such as heparin-induced thrombocytopenia (74 reports), vascular stent thrombosis (39 reports), and thrombosis (38 reports), along with reports of acute myocardial infarction (35 reports). These figures reflect the number of reports submitted, not confirmed rates of occurrence or proof that bivalirudin caused the event.